Literature DB >> 30668704

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?

Rodney H Falk1.   

Abstract

Entities:  

Year:  2019        PMID： 30668704     DOI： 10.1093/eurheartj/ehy697

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  3 in total

1.  Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.

Authors:  Rodney H Falk; Mia Haddad; Crystal R Walker; Sharmila Dorbala; Sarah A M Cuddy
Journal:  JACC CardioOncol       Date:  2021-10-19

2.  Rational Design, Synthesis, Characterization and Evaluation of Iodinated 4,4'-Bipyridines as New Transthyretin Fibrillogenesis Inhibitors.

Authors:  Alessandro Dessì; Paola Peluso; Roberto Dallocchio; Robin Weiss; Giuseppina Andreotti; Mariateresa Allocca; Emmanuel Aubert; Patrick Pale; Victor Mamane; Sergio Cossu
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

Review 3.  Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design.

Authors:  Lidia Ciccone; Nicoló Tonali; Susanna Nencetti; Elisabetta Orlandini
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.